3401 logo

Teijin Limited Stock Price

TSE:3401 Community·JP¥268.8b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

3401 Share Price Performance

JP¥1,394.50
29.50 (2.16%)
18.2% overvalued intrinsic discount
JP¥1,180.00
Fair Value
JP¥1,394.50
29.50 (2.16%)
18.2% overvalued intrinsic discount
JP¥1,180.00
Fair Value
Price JP¥1,394.50
AnalystConsensusTarget JP¥1,180.00

3401 Community Narratives

AnalystConsensusTarget·
Fair Value JP¥1.18k 18.2% overvalued intrinsic discount

Global Demand For Advanced Composites Will Expand Opportunities

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
JP¥1.18k
18.2% overvalued intrinsic discount
Revenue growth
-3.42% p.a.
Profit Margin
2.49%
Future PE
13.3x
Share price in 2028
JP¥1.54k

Snowflake Analysis

Fair value with moderate growth potential.

2 Risks
2 Rewards

Teijin Limited Key Details

JP¥993.2b

Revenue

JP¥764.4b

Cost of Revenue

JP¥228.8b

Gross Profit

JP¥311.0b

Other Expenses

-JP¥82.1b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 05, 2025
-426.24
23.04%
-8.27%
107.5%
View Full Analysis

About 3401

Founded
1918
Employees
20279
CEO
Akimoto Uchikawa
WebsiteView website
www.teijin.com

Teijin Limited engages in the fibers, films and sheets, composites, healthcare, and IT businesses worldwide. It offers aramid fibers; glass and carbon fibers, composite materials, and oxidized PAN fibers; polycarbonate sheets and films; high-density polyethylene porous films and materials; and microporous films. The company also provides PC resins, polyphenylene sulfide resins, molded parts, and additives; lightweight glass and carbon fiber reinforced composites for automotive applications; and polytrimethylene telephthalate products, artificial leather materials, polyester nanofibers, and recycled polyester fibers. In addition, it offers pharmaceuticals for bone and joint, respiratory, cardiovascular and metabolic, and other diseases; home oxygen therapy, non-invasive positive pressure ventilation, and sleep disordered breathing related devices, as well as sonic accelerated fracture healing system and community-based integrated care system businesses. Further, the company provides implantable medical devices and regenerative medical products. Additionally, it develops and implements engineering solutions for various issues, such as environmental pollution, energy supply stability, and aging-related workforce population decline. Teijin Limited was incorporated in 1918 and is headquartered in Tokyo, Japan.